CMN Weekly (2 February 2024) - Your Weekly CRISPR...
CMN Weekly
Feb. 2, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
2seventybio
Main focus: Novel cellular therapies for the treatment of cancer
Company stage: Clinical
Diseases: Cancer (undisclosed which programmes use gene editing)
Genome editing tool: megaTAL-based genome editing
Funding stage: Public (NASDAQ:TSVT)
Location: Cambridge, MA, USA
Website: https://www.2seventybio.com/
Pipeline: https://www.2seventybio.com/our-science
Gene editing Partnerships: Novo Nordisk
2seventy bio was recently formed as a spin-out company from bluebird bio. The company focuses on next generation cell-based therapies for the treatment of cancer. The company holds a priprietary megaTAL technology, which it applies for genomic engineering of its therapies. Currently, however, it is undisclosed which of the company's early phase programmes are actually incorporating the megaTAL technology.
Tags
Clinical Trials
IND Enabling
Phase I
Phase II
Phase III
